1-YEAR CONTROLLED RANDOMISED TRIAL OF PREVENTION OF EARLY POSTMENOPAUSAL BONE LOSS BY INTRANASAL CALCITONIN
1987; Elsevier BV; Volume: 330; Issue: 8574 Linguagem: Inglês
10.1016/s0140-6736(87)92619-5
ISSN1474-547X
AutoresJean‐Yves Reginster, Adelin Albert, MP Lecart, P Lambelin, D. Denis, Rita Deroisy, M Fontaine, P Franchimont,
Tópico(s)S100 Proteins and Annexins
Resumo79 women who had been menopausal for less than 36 months and who had not received any form of treatment to prevent bone loss were randomly assigned to a 12-month regimen of calcium 500 mg/day or calcium 500 mg plus intranasal salmon calcitonin 50 IU/day for 5 days per week. After 12 months of treatment bone mineral density had decreased in the calcium-only group by a mean of 3·16 (SEM 0·6)% (p<0·01) but had increased in the calcium plus calcitonin group by 1·38 (0·8)% (NS). The difference in response between the two treatment groups was also highly significant (p<0·01), as was the difference between values for hydroxyprolinuria/ creatininuria (p<0·01). Endogenous calcitonin levels rose significantly in the calcium group but remained unchanged in calcitonin-treated patients. Treatment by calcitonin and calcium was not followed by increased secretion of parathyroid hormone. The findings suggest that intranasal calcitonin can counteract early postmenopausal bone loss.
Referência(s)